ImmuCell Corp Files 8-K on Financials
Ticker: ICCC · Form: 8-K · Filed: Jan 10, 2025 · CIK: 811641
| Field | Detail |
|---|---|
| Company | Immucell Corp /De/ (ICCC) |
| Form Type | 8-K |
| Filed Date | Jan 10, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.10 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-results, operations, sec-filing
TL;DR
ImmuCell Corp dropped an 8-K on Jan 9th detailing financials. Check it out.
AI Summary
On January 9, 2025, ImmuCell Corporation filed an 8-K report detailing its financial results and operations. The filing provides information on the company's financial condition and results of operations, with exhibits attached. ImmuCell Corporation is incorporated in Delaware and headquartered in Portland, Maine.
Why It Matters
This 8-K filing provides investors with crucial updates on ImmuCell Corporation's financial performance and operational status, enabling informed investment decisions.
Risk Assessment
Risk Level: low — This filing is a standard 8-K reporting financial results and does not indicate any unusual or high-risk events.
Key Players & Entities
- ImmuCell Corporation (company) — Registrant
- January 9, 2025 (date) — Date of earliest event reported
- Portland, Maine (location) — Principal executive offices location
- 207-878-2770 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for ImmuCell Corporation?
The primary purpose of this 8-K filing is to report on ImmuCell Corporation's Results of Operations and Financial Condition, as well as to provide Financial Statements and Exhibits.
On what date was this 8-K filing made or effective?
The filing was made as of January 10, 2025, with the earliest event reported being January 9, 2025.
Where is ImmuCell Corporation's principal executive office located?
ImmuCell Corporation's principal executive office is located at 56 Evergreen Drive, Portland, Maine 04103.
What is the SEC file number for ImmuCell Corporation?
The SEC file number for ImmuCell Corporation is 001-12934.
What is the Standard Industrial Classification (SIC) code for ImmuCell Corporation?
The Standard Industrial Classification (SIC) code for ImmuCell Corporation is 2835, which corresponds to IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES.
Filing Stats: 544 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2025-01-10 07:10:26
Key Financial Figures
- $0.10 — nge on which registered Common Stock, $0.10 par value per share ICCC The NASDAQ
Filing Documents
- ea0227158-8k_immucell.htm (8-K) — 28KB
- ea022715801ex99-1_immucell.htm (EX-99.1) — 19KB
- 0001213900-25-002326.txt ( ) — 220KB
- iccc-20250109.xsd (EX-101.SCH) — 3KB
- iccc-20250109_lab.xml (EX-101.LAB) — 33KB
- iccc-20250109_pre.xml (EX-101.PRE) — 22KB
- ea0227158-8k_immucell_htm.xml (XML) — 3KB
02. Results of Operations
Item 2.02. Results of Operations and Financial Condition On January 9, 2025 ImmuCell Corporation (the "Company") issued a press release announcing its preliminary, unaudited product sales for the year ended December 31, 2024. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
01. Financial
Item 9.01. Financial (d) Exhibits . The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed: 99.1 Press Release of ImmuCell Corporation dated January 9, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUCELL CORPORATION Date: January 10, 2025 By: /s/ Michael F. Brigham Michael F. Brigham President, Chief Executive Officer and Principal Financial Officer 2 Exhibit Index Exhibit No. Description 99.1 Press Release of ImmuCell Corporation dated January 9, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3